Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
The White House has promised reforms in the health care sector, such as changing the bidding process for drugs and shortening the FDA approval process. It is yet to be seen how much headway it actually can make with these reforms.
Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.
The December 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Short interest in Pfizer Inc. (NYSE: PFE) increased to 58.84 million shares from the previous 57.98 million. The stock was trading at $39.29 Thursday morning, within a 52-week range of $33.97 to $44.90.
The number of Merck & Co. Inc. (NYSE: MRK) shares short decreased slightly to 24.38 million from 24.67 million in the previous period. Its shares were trading at $91.44, in a 52-week range of $72.05 to $92.64.
Bristol-Myers Squibb Co. (NYSE: BMY) saw its short interest drop sharply to 74.32 million shares from the previous reading of 97.22 million. Shares traded at $63.16, in a 52-week trading range of $42.48 to $64.75.
The number of shares short in AbbVie Inc. (NYSE: ABBV) increased slightly to 68.83 million from the previous 68.40 million. The stock was trading at $89.85, and its 52-week range is $62.66 to $92.99.
Eli Lilly and Co.’s (NYSE: LLY) short interest increased to 11.58 million shares from the previous 10.55 million. The stock was trading at $131.11. The 52-week range is $101.36 to $137.00.
Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) short interest was 67.38 million, down from the previous level of 67.67 million. Shares were trading at $10.05, in a 52-week range of $6.07 to $20.21.
24/7 Wall St.In 20 Years, I Haven’t Seen A Cash Back Card This Good
After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers.
A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.
Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.